MindWalk Holdings Corp. (NASDAQ:HYFT) Receives $5.00 Average Target Price from Analysts

Shares of MindWalk Holdings Corp. (NASDAQ:HYFT) have been assigned a consensus rating of “Hold” from the five ratings firms that are currently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, two have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $5.00.

A number of research firms have recently commented on HYFT. Wall Street Zen upgraded MindWalk from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Zacks Research cut MindWalk from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 28th. HC Wainwright reissued a “buy” rating on shares of MindWalk in a report on Monday, July 20th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of MindWalk in a research report on Wednesday, July 15th.

MindWalk Stock Performance

HYFT opened at $1.42 on Wednesday. The company has a debt-to-equity ratio of 0.26, a current ratio of 2.80 and a quick ratio of 2.72. The firm has a fifty day moving average price of $1.44 and a 200 day moving average price of $1.37. MindWalk has a 1 year low of $0.99 and a 1 year high of $2.99. The stock has a market cap of $66.33 million, a P/E ratio of -6.45 and a beta of 0.84.

MindWalk (NASDAQ:HYFT) last released its quarterly earnings results on Wednesday, July 22nd. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.01). MindWalk had a negative net margin of 89.65% and a negative return on equity of 92.61%. The firm had revenue of $3.03 million for the quarter. Equities research analysts anticipate that MindWalk will post -0.21 earnings per share for the current year.

Institutional Investors Weigh In On MindWalk

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Virtu Financial LLC acquired a new position in MindWalk during the fourth quarter worth $51,000. GSA Capital Partners LLP acquired a new stake in shares of MindWalk in the second quarter valued at about $55,000. Bridgeway Capital Management LLC purchased a new stake in shares of MindWalk during the fourth quarter worth about $91,000. Bank of Montreal Can raised its position in shares of MindWalk by 81.0% during the 4th quarter. Bank of Montreal Can now owns 54,750 shares of the company’s stock worth $100,000 after purchasing an additional 24,500 shares during the last quarter. Finally, XTX Topco Ltd raised its position in shares of MindWalk by 118.6% during the 4th quarter. XTX Topco Ltd now owns 81,721 shares of the company’s stock worth $149,000 after purchasing an additional 44,331 shares during the last quarter. Hedge funds and other institutional investors own 6.70% of the company’s stock.

About MindWalk

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.